1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Europe Late Stage Chronic Kidney Disease Drugs Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Europe Late Stage Chronic Kidney Disease Drugs Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 High Prevalence of Diseases Implying to Chronic Kidney Diseases
5.2 Market Opportunities
- 5.2.1 Introduction of New Late Stage Chronic Kidney Disease Drugs
5.3 Future Trends
- 5.3.1 Introducing New Preclinical Models to Improve Target Validation and Understand Disease Development
5.4 Impact of Drivers and Restraints
6. Europe Late Stage Chronic Kidney Disease Drugs Market Regional Analysis
6.1 Europe Late Stage Chronic Kidney Disease Drugs Market Overview
6.2 Europe Late Stage Chronic Kidney Disease Drugs Market Revenue 2017-2027 (US$ Million)
6.3 Europe Late Stage Chronic Kidney Disease Drugs Market Forecast Analysis
7. Europe Late Stage Chronic Kidney Disease Drugs Market Analysis – by Product Type
7.1 Calcimimetics
- 7.1.1 Overview
- 7.1.2 Calcimimetics: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Vitamin D
- 7.2.1 Overview
- 7.2.2 Vitamin D: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Sterols
- 7.3.1 Overview
- 7.3.2 Sterols: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Potassium Binders
- 7.4.1 Overview
- 7.4.2 Potassium Binders: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Calcium-Based Phosphate Binders
- 7.5.1 Overview
- 7.5.2 Calcium-Based Phosphate Binders: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8. Europe Late Stage Chronic Kidney Disease Drugs Market Analysis – by Indication
8.1 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
- 8.1.1 Overview
- 8.1.2 Late Stage Chronic Kidney Disease Induced Hyperparathyroidism: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
- 8.2.1 Overview
- 8.2.2 Late Stage Chronic Kidney Disease Induced Hyperphosphatemia: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Late Stage Chronic Kidney Disease Induced Hyperkalaemia
- 8.3.1 Overview
- 8.3.2 Late Stage Chronic Kidney Disease Induced Hyperkalaemia: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9. Europe Late Stage Chronic Kidney Disease Drugs Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Late Stage Chronic Kidney Disease Induced Hyperkalaemia: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Online Pharmacies
- 9.2.1 Overview
- 9.2.2 Late Stage Chronic Kidney Disease Induced Hyperkalaemia: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Retail Pharmacies
- 9.3.1 Overview
- 9.3.2 Late Stage Chronic Kidney Disease Induced Hyperkalaemia: Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
10. Europe Late Stage Chronic Kidney Disease Drugs Market – Europe Analysis
10.1 Europe
- 10.1.1 Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.1.1.1 Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 UK:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.1.1 UK: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.1.1.1.2 UK: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.1.1.1.3 UK: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.1.1.2 Germany:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.2.1 Germany: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.1.1.2.2 Germany: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.1.1.2.3 Germany: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.1.1.3 France:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.3.1 France: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.1.1.3.2 France: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.1.1.3.3 France: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.1.1.4 Russia:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.4.1 Russia: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.1.1.4.2 Russia: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.1.1.4.3 Russia: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.1.1.5 Italy:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.5.1 Italy: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.1.1.5.2 Italy: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.1.1.5.3 Italy: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
- 10.1.1.6 Rest of Europe:
Europe Late Stage Chronic Kidney Disease Drugs Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.6.1 Rest of Europe: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Product Type
- 10.1.1.6.2 Rest of Europe: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Indication
- 10.1.1.6.3 Rest of Europe: Europe Late Stage Chronic Kidney Disease Drugs Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Europe Late Stage Chronic Kidney Disease Drugs Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 AbbVie Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Amgen
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 AstraZeneca
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Sanofi
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Kyowa Kirin Co., Ltd
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Takeda Pharmaceutical Company Limited
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Astellas Pharma Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bayer AG
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Vifor Pharma Management Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 Akebia Therapeutics, Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For Europe Late Stage Chronic Kidney Disease Drugs Market
